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The variation in individual responses to exogenous agents has been shown to be exceptionally
wide. It is because of this large diversity of responsiveness that risk factors to environmentally
induced diseases have been difficult to pinpoint, particularly at low exposure levels. Opportunities
now exist for studies of host factors in environmentally induced cancer or other diseases in which
an environmental component can be presumed. Many of the studies have shown an elevated
disease proneness for individuals carrying the potential at-risk alleles of metabolic genes, but a
number of controversial results have also been reported. One possible explanation for the
divergent findings is lack of knowledge of the other potentially relevant genotypes for a given
exposure. This paper gives an overview of the published data on combinations of metabolic
genotypes in relation to individual susceptibility to environmental toxicants. Environ Health
Perspect 105(Suppl 4):755-758 (1997)
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Introduction
People are exposed to agents (chemical,
physical, and biological) that may con-
tribute to the prevalence ofgenetic damage
and chronic diseases in the population.
Many ofthe diseases are affected by both
host factors and the external environment.
For instance, although carcinogenesis in
humans is known to be significantly influ-
enced by external factors, the metabolic
activation or inactivation of the procar-
cinogens may modulate the process. This is
best exemplified by tobacco smoking; ciga-
rette smoking is the main cause of lung
cancer but only a minority of smokers
develop pulmonary cancers.
Recent findings suggest that inherited
differences in metabolic capacity may
in fact play a primary role in susceptibility
to environmentally induced diseases
(1-4). Genetic polymorphisms exist in a
number ofphase I (activating) and phase II
(inactivating) enzymes. It is conceivable
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that individuals with genotypes associated
with a more efficient activating enzyme
and a less efficient inactivating enzyme
might be at particularly high risk ofadverse
health effects, ifexposed to toxicants.
Phase I enzymes cytochrome P450 lAl
(CYPlA1) and 2D6 (CYP2D6) are the
most studied candidates as modifiers of
individual responses to environmental
agents (1-4). The rare Val and m2 alleles
of CYPIAJ gene (frequencies 1-2% in
Caucasians) may increase individual cancer
risk by heightening aryl hydrocarbon
hydroxylase (AHH) enzyme inducibility.
In contrast, the segment of Caucasians
(approximately 7%) who possess two defi-
cient CYP2D6alleles (poor metabolizer
[PM] genotype) may be at decreased risk of
cancer (1-4), but at increased risk of sev-
eral central nervous system disorders (5-8).
Among phase II enzymes, N-acetyl-
transferases (NATs) and glutathione S-
transferases (GSTs) have attracted most of
the recent interest. The GST MI
(GSTM1) and TI (GSTTI) genes are
polymorphic so that the absence ofenzyme
activity results from a homozygous deletion
ofthe respective gene, called the null geno-
type (9,10). About 50% of Caucasians
have the GSTMI null genotype, which
may pose an increased risk ofvarious envi-
ronmentally induced cancers (11-14). The
GSTTI null genotype, which putatively
has a frequency of 15 to 25% in
Caucasians, has been associated with
enhanced susceptibility to primary brain
tumors (astrocytoma and meningioma)
(15), and to myelodysplastic syndromes,
which are clonal proliferative disorders of
bone marrow that often progress to acute
myeloid leukemia (16).
The human N-acetylation polymor-
phism is demonstrable by individual varia-
tions in metabolism ofseveral substrates,
including sulfamethazine and isoniazid
(17). The differences in the metabolism of
these compounds distinguish phenotypically
slow and fast acetylators. The slow acetyla-
tors, whose frequency worldwide ranges
from about 10% to more than 90% (18),
may be at increased risk of arylamine-
induced cancers (19-22).
Previous studies on acetylation poly-
morphisms have focused on the NAT2
gene locus, and allelic variants of NAT2
gene correlate with differences in acetyla-
tion capacity (23-26). However, recent
evidence shows structural heterogeneity in
the NATI gene locus also, correlating with
N-acetylation activity distinct from that
typified by isoniazid and sulfamethazine
(27,28). It has been suggested that NATI
is primarily responsible for NAT activity in
human uroepithelium (29), and correla-
tion between NATI polyadenylation signal
polymorphism and risk ofcolorectal cancer
has been reported (30).
Given the number and variability in
expression of carcinogen-metabolizing
enzymes and the complexity of chemical
exposures, assessment of a single poly-
morphic genotype cannot be expected
to be sufficient for evaluating individual
susceptibility to environmental agents.
Establishment of a broader risk profile for
each individual or subgroup is required.
The relatively scarce data presently available
on the combinations ofsusceptible geno-
types in individual responses to toxicants is
reviewed below.
Combined Genotypes and
Disease Susceptibility
The first observation of the combined
effect ofmetabolic genes in disease prone-
ness was by Hayashi and co-workers (31)
who described a 5.8-fold relative risk (95%
CI 2.3-13.3) for all lung cancer types and a
9.1-fold relative risk (95% CI 3.4-24.4)
for squamous cell carcinoma ofthe lung in
Japanese individuals who were homozygous
for the CYPIAI Val allele and concurrently
lacked the GSTM1 gene. Asimilar, although
less pronounced risk (OR 3.0, 95% CI
1.2-7.2) for developing this histological
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type of lung cancer was attributed to
Caucasians carrying the CYPIAI allele m2,
and having the GSTMI null genotype
(32). Subsequent evaluation of the effect
ofsmoking in the Japanese study revealed
that this genotype composition may pose an
especially remarkable risk for squamous cell
carcinoma (OR41.0, 95% CI 8.7-193.6) at
low-dose cigarette smoking (33). These
findings are consistent with the notion that
some procarcinogens in cigarette smoke
are activated by CYPlAI and inactivated
by GSTM1.
The major importance of the high
AHH inducibility in combination with
homozygous GSTMI null genotype in
environmentally induced lung cancer is
further underlined by the observation that
the expressing GSTM1 gene appears to
have a protective effect against bronchial
cancer among individuals with inducible
CYPlAI enzyme (34). In contrast, no mul-
tiplicative effect was found for CYPIAI and
GSTM1 genotypes in a study which found
a somewhat higher breast cancer risk (OR
1.6, 95% CI 1.2-23.4) for postmeno-
pausal, light smokers with the CYPIAI
Val allele compared to those without the
allele (35). Interestingly, the presence of
the GSTMI gene was recently correlated
with induction of only low levels of
CYPlAl mRNA (36).
The protecting role of GSTMI gene in
environmental exposures was supported by
a study among Finnish asbestos workers,
where the GSTMJ null genotype was asso-
ciated with a 2-fold risk (OR 1.8, 95% CI
1.0-3.5) ofasbestos-associated malignant
mesothelioma (37). Rather surprisingly,
the NAT2 slow acetylator genotype
appeared as a similarly important modifier
of the mesothelioma risk (OR 2.1, 95%
CI 1.1-4.1). Moreover, a striking interac-
tion was observed between these geno-
types; highly asbestos-exposed workers
without the GSTMI gene and with the
NAT2 slow acetylator genotype were 7.4-
fold (95% CI 1.6-34.0) more prone to
develop the neoplasm than fast acetylators
with GSTMI gene.
N-acetylation may be a comparably
important detoxification step in environ-
mental exposures, as is glutathione conju-
gation. Thus, the combination of NATi
and NAT2 susceptible genotypes may be a
particularly unfavorable genotype composi-
tion in arylamine exposures. The recently
observed association between increased risk
(OR 1.9, 95% CI 1.2-3.6) of colorectal
cancer and the fast NATi acetylator allele
(NATI*10) was most apparent (OR 2.8,
95% CI 1.4-5.7) among the fast NAT2
acetylators (30).
Given the substrate specificities of the
GSTs, individuals with null genotypes at
both GSTMI and GSTTI may be at par-
ticular risk of environmentally induced
cancers. To date, only a few studies have
addressed this issue comprehensively.
Warwick and co-workers (38) studied the
role ofcombinations of CYP2D6, GSTMI,
and GSTTI genotypes in susceptibility to
cervical intraepithelial neoplasia and squa-
mous cell carcinoma of the lung. In this
study, no combined effect was detected for
the two GST genes. However, the CYP2D6
extensive metabolizer (EM) genotype and
the GSTTI null genotype were shown to
be important risk factors for these pul-
monary disorders, both individually and in
combination. The GSTTI null and
CYP2D6 PM genotypes were shown
recently to also increase the risk for two
common pituitary brain tumors, astrocy-
toma and meningioma, but no interactive
effects between the genotypes were identi-
fied (15). Moreover, in another study, no
association between the CYP2D6 or
GSTMJ genotypes and susceptibility to the
pituitary tumors was detected (39).
Since the recently observed association
between the GSTTI null genotype and
total ulcerative colitis was also shown to be
uninfluenced by the GSTMI genotype
(40), the yet published data does not indi-
cate concurrent deficiency ofthe GSTMI
and GSTTI genes playing an important
role in individual disease proneness.
However, our preliminary findings that
this genotype composition poses about a
2.5-fold risk of lung cancer compared to
the presence of both of the GST genes
(Saarikoski et al., unpublished data) war-
rant more thorough evaluation of this
issue. Finally, the combined effect of
CYP2EI and GSTMI genotypes was exam-
ined in a study suggesting a 2.5-fold risk of
hepatocellular carcinoma for individuals
with wild-type CYP2E1 gene compared to
those with at least one variant allele in the
transcription regulatory area of the gene
(41). Again, no modulating effect was
found for the GSTMI genotype.
Exposure Markers and
Combined Susceptibility
Genotypes
Efforts to relate metabolic phenotype or
genotype to risk of environmentally
induced diseases are now extending to
studies on various markers ofexposure such
as DNA adduct formation and indicators of
cytogenetic damage, e.g., sister chromatid
exchanges and micronuclei.
Genotoxic agents can form DNA
adducts and cytogenetic changes via a com-
plex metabolic pathway that includes
CYPlAl; intermediates can be detoxified
by conjugation through pathways including
GSTs and NATs. A recent study failed to
support the importance of this metabolic
pathway by reporting lack ofany significant
association between DNA adduct levels and
CYPIAI and GSTMI genotypes among
nonsmoking fire fighters (42). No relation
was found between these genes and the B-
and T-micronuclei formation in PAH-
exposed chimney sweeps (43,44); the only
statistically significant deviation was a 60%
increase in aromatic DNA-adduct levels in
GSTMI null chimney sweeps without any
CYPIAI m2 alleles compared to controls
with the same genotype composition (44).
However, the GSTMI null genotype
has been associated with significantly higher
aromatic DNA adduct levels in bus mainte-
nance workers with the NAT2slow acetyla-
tor genotype compared to those with the
GSTMI gene (45). In a similar study, non-
smoking bus drivers with NAT2slow acety-
lator genotype and GSTMI null genotype
had the highest levels ofboth DNA adducts
and cytogenetic damage (46). Moreover,
aminobiphenyl-hemoglobin adduct levels
are most elevated in smokers possessing this
combination of genotypes compared to
smokers with other combinations (47).
Carcinogenic DNA adduct levels in the
mucosa ofthe urinary bladder were highest
in arylamine-exposed individuals who had
inherited both the slow NAT2 acetylator
genotype and the rapid NAT1 acetylation-
associated allele NAT]*10 (48), further
addressing the potential importance of
individual acetylation capacity.
Conclusion
Knowledge ofthe genetic basis forvariations
in human metabolic capacity has opened
new possibilities for studies focusing on the
role ofhost factors in susceptibility to envi-
ronmentally induced diseases. Rapid
advances in methodology that determines
potential metabolic at-risk genotypes, in
combination with exposure markers such
as DNA adduct levels in target (surrogate)
tissues, may soon allow us to identify
susceptible individuals and subgroups in
environmentally exposed populations.
However, the establishment of combined
impact .of all relevant genes for a given
exposure is anticipated to be a prerequisite
for this.
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